C4 Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $8,468 | $6,641 | $6,152 | $11,016 |
Gross Profit | 8,468 | 6,641 | 4,351 | 11,016 |
EBITDA | -24,276 | -23,343 | -24,725 | -19,937 |
EBIT | -24,596 | -23,635 | -25,129 | -20,365 |
Net Income | -21,843 | -23,635 | -25,129 | -20,486 |
Net Change In Cash | 8,468 | 6,641 | 6,152 | 11,016 |
Free Cash Flow | -25,966 | -1,611 | -30,008 | -22,156 |
Cash | 32,425 | 78,610 | 61,274 | 74,603 |
Basic Shares | 136,080 | 130,696 | 126,074 | 116,784 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $35,947 | $35,584 | $20,756 | $31,096 |
Gross Profit | 27,972 | 35,584 | 13,019 | 31,096 |
EBITDA | -102,914 | -103,367 | -127,960 | -124,283 |
EBIT | -104,873 | -105,185 | -129,840 | -125,959 |
Net Income | -104,994 | -105,316 | -132,493 | -128,175 |
Net Change In Cash | 35,947 | 35,584 | 20,756 | 31,096 |
Cost of Revenue | -46,370 | |||
Free Cash Flow | -99,301 | -65,337 | -108,546 | -111,435 |
Cash | 74,603 | 55,499 | 126,590 | 29,754 |
Basic Shares | 82,894 | 69,372 | 49,640 | 48,861 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.16 |
2026-06-30 | -$0.18 |
2026-03-31 | -$0.20 |
2025-12-31 | -$0.18 |